Mitochondrial Defunctionalization Supresses Tim-3-Galectin-9 Secretory Pathway in Human Colorectal Cancer Cells and Thus Can Possibly Affect Tumor Immune Escape

Svetlana S. Sakhnevych; Inna M. Yasinska; Elizaveta Fasler-Kan; Elizaveta Fasler-Kan; Vadim V. Sumbayev

doi:10.3389/fphar.2019.00342

Frontiers in Pharmacology (Apr 2019)

Mitochondrial Defunctionalization Supresses Tim-3-Galectin-9 Secretory Pathway in Human Colorectal Cancer Cells and Thus Can Possibly Affect Tumor Immune Escape

Svetlana S. Sakhnevych,
Inna M. Yasinska,
Elizaveta Fasler-Kan,
Elizaveta Fasler-Kan,
Vadim V. Sumbayev

Affiliations

Svetlana S. Sakhnevych: Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham, United Kingdom
Inna M. Yasinska: Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham, United Kingdom
Elizaveta Fasler-Kan: Department of Pediatric Surgery and Department of Biomedical Research, Children's Hospital, Inselspital, University of Bern, Bern, Switzerland
Elizaveta Fasler-Kan: Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
Vadim V. Sumbayev: Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham, United Kingdom

DOI: https://doi.org/10.3389/fphar.2019.00342
Journal volume & issue: Vol. 10

Abstract

Read online

The Tim-3-galectin-9 secretory pathway is known to protect various types of cancer cells against host immune surveillance. We found that pharmacologically induced mitochondrial dysfunction leads to a reduced galectin-9 expression/exocytosis in human colorectal cancer cells and re-distribution of this protein (the effect described for various cellular proteins) into mitochondria.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords